

International Conference on **CANCER BIOLOGY AND THERAPEUTICS**

May 11, 2023 | Webinar

**Multitarget inhibitors as anticancer onco immunomodulatory properties****Eva Falomir***Jaume I University, Spain*

Fourteen triazole derivatives have been developed using simply synthetic strategies. The structures were designed by docking studies based on previous results to target both PD-L1 and VEGFR-2 and, also the effect on oncogene c-Myc was studied. The antiproliferative activity on monocultures of several tumor cell lines (HT-29, A-549 and MCF-7), and on other human cell lines as HEK-293 was studied. Then, the effect on anticancer targets (PD-L1, VEGFR-2 and c-Myc) was determined. Later, the effect on cancer cell viability when co-cultured with immune cells (Jurkat T cells or THP-1) was also studied. And, finally, the potential anti-inflammation action was determined by measuring the effect of some selected compounds on IL-6 secretion to cell media in monocultures of cancer and immune cells and in cocultures of both types of cells.

**Biography**

Dr. Eva Falomir studied Chemistry at the Valencia University, Spain and graduated as MS in 1994. She then joined the research group of Prof. Carda at Jaume I University (UJI). She received her PhD degree in 1998 at the same institution. After two years postdoctoral fellowship supervised by Dr A. Fürstner at Max-Planck Institute, Germany she obtained the position of an Associate Professor at UJI. In 2022, she got a Full Professor position in the same university. She has published more than 100 research articles in SCI(E) journals.